Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy

Onkologie

Volumn 31, Issue 3, 2008, Pages 91-96

  Veldwijk, Marlon R ^a,b   Berlinghoff, Simone ^b   Jauch, Anna ^a   Laufs, Stephanie ^b   Zeller, W Jens ^b   Wenz, Frederik ^a   Fruehauf, Stefan ^a,c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Paracelsus Klinik   (Germany)

^d Paracelsus Klinik   (Germany)

Author keywords

Adeno associated virus; FISH; Mesothelioma; Mouse model; Suicide gene therapy

Indexed keywords

GANCICLOVIR; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MESOTHELIOMA; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; SCID MOUSE; SUICIDE GENE THERAPY; TUMOR XENOGRAFT; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; MESOTHELIOMA; MICE; MICE, SCID; TRANSDUCTION, GENETIC;

EID: 40449122523     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113504     Document Type: Article

References (30)

1. Rusch VW: Mesothelioma and less common tumors; in Pearson FG, Deslauriers J, Ginsberg RJ, Hiebert CA (eds): Thoracic Surgery. New York, Edingburgh, London, Melbourne, Tokyo, Churchill Livingstone, 1995, p 1083.
2. Gordon W Jr, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT: Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982;8:19-25.
3. Ryan CW, Herndon J, Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113(suppl 1):66S-73S.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
5. Junker K, Lindner M, Schuette W, Stahel R: Diagnostik und Therapie des Pleuramesothelioms. Onkologie 2007;30(suppl 1):11-16.
6. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-825.
7. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR: Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-317.
8. Mackay B, Lukeman JM, Ordóñez NG: Tumors of the pleura and chest wall; in Tumors of the Lung. Major Problems in Pathology. Philadelphia, W.B. Saunders, 1991, vol 24, pp 323-364.
9. Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A: Characterization of a human malignant mesothelioma cell line (HMESO-1): a biphasic solid and ascitic tumor model. Cancer Res 1987;47:3199-3205.
10. Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, Haeder M: Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 1988;37:158-171.
11. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-2923.
12. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA Jr, Carney D, Minna JD, Mulshine JL: NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996;24:32-91.
13. Jooss K, Chirmule N: Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003;10:955-963.
14. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P, David-Ameline J, Moullier P: Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998;9:695-706.
15. Laufs S, Gentner B, Nagy KZ, Jauch A, Benner A, Naundorf S, Kuehlcke K, Schiedlmeier B, Ho AD, Zeller WJ, Fruehauf S: Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood 2003;101:2191-2198.
16. Grimm D, Kern A, Rittner K, Kleinschmidt JA: Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998;9:2745-2760.
17. Veldwijk MR, Berlinghoff S, Laufs S, Hengge UR, Zeller WJ, Wenz F, Fruehauf S: Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. Cancer Gene Ther 2004;11:577-584.
18. Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, Zeller WJ, Fruehauf S: Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002;6:272-278.
19. Veldwijk MR, Schiedlmeier B, Kleinschmidt JA, Zeller WJ, Fruehauf S: Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks. Eur J Cancer 1999;35:1136-1142.
20. Berlinghoff S, Veldwijk MR, Laufs S, Maser HP, Jauch A, Wenz F, Zeller WJ, Fruehauf S: Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy. Lung Cancer 2004;46:179-186.
21. Abati A, Sanford J, Fetsch P, Pass H: Detection of aneuploidy in mesothelioma cell lines by fluorescence in situ hybridization (FISH). Diagn Cytopathol 1997;16:375-377.
22. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ: Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995;59:835-844.
23. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993;53:4349-4355.
24. Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA: Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 1986;20:191-201.
25. Decker HJ, Li FP, Bixenman HA, Sandberg AA: Chromosome 3 and 12p rearranged in a well-differentiated peritoneal mesothelioma. Cancer Genet Cytogenet 1990;46:135-137.
26. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet 2001;127:93-110.
27. Aerssens J, Guo C, Vermeesch J, Baens M, Browne D, Litt M, Van Den Berghe H, Marynen P: A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13). Cytogenet Cell Genet 1995;71:268-275.
28. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR: Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999;24:238-242.
29. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-756.
30. Veldwijk MR, Fruehauf S, Schiedlmeier B, Kleinschmidt JA, Zeller WJ: Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells. Cancer Gene Ther 2000;7:597-604.